Osteoclasts are cells that break down bone; however, excessive bone loss leads to conditions such as osteoporosis. When three proteins called RANKL bind to three receptors called RANK on the osteoclasts’ surfaces, the osteoclasts go to work. Warren et al. linked three mutant versions of RANKL protein together to generate an inhibitor of RANK (see the Perspective by Ou-Yang and Siegel). Two of the proteins bound more strongly to RANK, and the third protein could not bind to RANK. This engineered RANKL variant bound to RANK without activating the receptor, preventing osteoclasts from breaking down bone in mice…
John F. Foley
Want To Publish your Group Article?
Click HERE to send us your group Article for publishing on our website.
- alzheimer Alzheimers Disease animal model antibiotic resistance antibiotics Bacteria Brain breast cancer cancer cell-signaling clinical trials CRISPR diabetes disease/medicine DNA drug drug research Gene Expression general health Gene therapy Genetics genetics & genomics Genomics HIV immunology immunotherapy infectious disease Malaria microbiology microbiome mutation neuroscience new therapy obesity Parkinson's disease stem cells T cells techniques therapy treatment tumor vaccine virology virus Zika virus